5 July 2009

ImmuPharma ponders funding

01/07/2008 Robert Tyerman

Drug discoverer ImmuPharma is understood to be contemplating raising between £1.5 million and £5 million at around 60p to fund developments with a range of products. These include Lupuzor, its key IPP-201101 treatment candidate for Lupus Erythematosus, a chronic auto-immune disease that damages skin, joints, blood vessels, various organs and the nervous system.

The AIM-quoted company awaits the results of a 200-patient Phase IIb efficacy study for Lupuzor, due this autumn. Recently, ImmuPharma announced that pre-clinical trial data showed that another of its products, IPP-204106, could curb the growth of many human cancer cell lines, with ‘in vivo’ studies showing most tumours completely eradicated and survival time increased without additional treatment.

Richard Warr, chairman of London-based ImmuPharma, commented on IPP-204106, ‘This exciting new drug has tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic.’ But most analysts see Lupuzor as the company’s biggest potential winner.

ImmuPharma is in collaboration with CNRS, the national scientific research centre of France, which is providing it with access both to leading scientists and possible grant opportunities. Being a development company, ImmuPharma lost £3.3 million last year, which it closed with cash of £2.9 million.

Shares in ImmuPharma have fluctuated between 40.5p and 84.5p over the past three years and now stand at 65.75p, valuing the company at £48 million. They offer significant speculative potential over the medium term.

Companies: ImmuPharma

Subscribe today

Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations.

To subscribe today with a half-price offer and gain immediate access to all the recommendations, click here.

Xforex proudly presents a great opportunity

Get 20% bonus on your first deposit and a financial advisor serving you 24/7. For experienced traders – xforex extreme feature – follow our top trader LIVE!

New Issues on Aim Research Report 2009

The new survey into new AIM companies focusing on IPO activity over the closing months of 2008. The report itself contains information on the brokers who are most able to raise cash in the current environment and the sectors that are attracting institutional investment. Buy the new issues on Aim research report.

Liquidity Drivers on AIM research

In the first ever deep analysis of trading values and volumes on AIM, Growth Company Investor, in association with BDO Stoy Hayward, will be shining their research light on the pre-eminent companies on AIM. Buy the Liquidity Drivers on AIM research report today.

Spotlight on AIM 2009 research

The fifth annual examination of the entire AIM market, detailing the fastest growing companies on the junior market, aswell as the most profitable and the least profitable businesses. Buy the Spotlight on AIM 2009 research report today.

Cash Shells Special Report 2009

Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy Cash Shells 2009 Research Report today.

Popular News

Latest News

Agriterra buys corn from local farmers at half the international price

Agriterra moots sugar move 03/07/2009

Phil Edmonds’ African food group Agriterra expects a turnaround to profits as it contemplates a move into sugar.

Tags: Breaking-even , Emerging markets , Fundraisings , Turnaround

Sector: Food Producers

Companies: Agriterra (formerly White Nile)

Bglobal wins funding 03/07/2009

‘Smart metering’ specialist Bglobal has obtained up to £15 million asset funding from Barclays Asset Sales & Finance.

Tags: Cash , Fundraisings

Sector: Support Services

Companies: Bglobal

Jubilee in £26m Braemore bid 03/07/2009

Jubilee Platinum is offering shares to buy fellow AIM counter, smelting and refining specialist Braemore Resources.

Tags: AIM , Mergers & acquisitions , Penny shares

Sector: Mining

Companies: Jubilee Platinum , Braemore Resources

More News

Sectors

Vitesse Media Events